Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shenzhen Salubris Pharmaceuticals Co: Clinical Trials & FDA Approval Profile

Shenzhen Salubris Pharmaceuticals Co (Global / Institutional) sponsors 23 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (3 recruiting now), 13 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)371 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shenzhen Salubris Pharmaceuticals Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)23
Active Pipeline (Recruiting Now)9 (3)
Completed vs Stopped Early13 / 0 (0.0%)
Median Closed Actual Enrollment371 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shenzhen Salubris Pharmaceuticals Co
Hospital Research SiteLocationShared Protocols
Peking University First HospitalBeijing, Beijing Municipality3
West China Hospital of Sichuan UniversityChengdu, Sichuan2
Peking University Third HospitalBeijing, Beijing Municipality2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shenzhen Salubris Pharmaceuticals Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06500689To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan IsoproxilPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Shenzhen Salubris Pharmaceuticals Co Interactive Dossier, benchmark peers in Cardiovascular and Thrombosis, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI